CPSF3 and Cowden disease: The development of new drugs with trypanocidal activity for treating CD is crucial, as currently, only one compound, a benzoxaborole derivative (DNDI-6148, CPSF3 inhibitor), has reached phase I in clinical trials (Padilla et al., 2022; Tarleton, 2023).